850 reports of this reaction
2.7% of all PANITUMUMAB reports
#6 most reported adverse reaction
SKIN TOXICITY is the #6 most commonly reported adverse reaction for PANITUMUMAB, manufactured by Amgen, Inc. There are 850 FDA adverse event reports linking PANITUMUMAB to SKIN TOXICITY. This represents approximately 2.7% of all 31,648 adverse event reports for this drug.
Patients taking PANITUMUMAB who experience skin toxicity should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SKIN TOXICITY is a less commonly reported adverse event for PANITUMUMAB, but still significant enough to appear in the safety profile.
In addition to skin toxicity, the following adverse reactions have been reported for PANITUMUMAB:
SKIN TOXICITY has been reported as an adverse event in 850 FDA reports for PANITUMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
SKIN TOXICITY accounts for approximately 2.7% of all adverse event reports for PANITUMUMAB, making it a notable side effect.
If you experience skin toxicity while taking PANITUMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.